Physician profile
David Redding
NPI 1710181391
$21,992.54
in general payments reported to CMS, 2019-2025
45 companies · $4,616 in 2025
The $4,616 reported for 2025 was more than what 83% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,657 · 2020: $1,455 · 2021: $2,513 · 2022: $3,613 · 2023: $3,842 · 2024: $3,297 · 2025: $4,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $150 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,570.30 |
| Consulting Fee | $150.49 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,504.72 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $2,334.72 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,696.99 | 2019-2025 | Dupixent |
| Csl Behring | $1,526.03 | 2019-2025 | Haegarda, Andembry, Hizentra |
| Glaxosmithkline, LLC. | $1,504.00 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Abbvie INC. | $1,258.24 | 2021-2025 | |
| Pfizer INC. | $1,169.13 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $994.33 | 2020-2025 | Takhzyro, Cuvitru, Hyqvia |
| Optinose US, INC. | $928.49 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $886.02 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $730.08 | 2021-2025 | Orladeyo |
| Covis Pharma Gmbh | $549.39 | 2021-2023 | |
| Pharming Healthcare, INC. | $533.43 | 2020-2025 | Ruconest |
| Blueprint Medicines Corporation | $532.44 | 2023-2025 | Ayvakit |
| Incyte Corporation | $525.23 | 2022-2025 | Opzelura |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Redding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.